Literature DB >> 32052427

KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer.

Ran Miao1, Cong-Cong Dai1, Lin Mei2, Jun Xu3, Shan-Wen Sun3, Yun-Long Xing1, Li-Sheng Wu1, Ming-Hai Wang2, Ji-Fu Wei4.   

Abstract

N6-methyladenosine (m6A) modification regulatory proteins are involved in the development of many types of cancer. KIAA1429 serves as a scaffold in bridging the catalytic core components of the m6A methyltransferase complex. The role of KIAA1429 in gastric cancer and its related mechanism has not been reported upon. The expression of KIAA1429 was detected in human gastric cancer tissues and cell lines by quantitative real-time polymerase chain reaction and western blot. The effects of KIAA1429 on gastric cancer proliferation were evaluated by cell counting kit assays, colony formation assays, flow cytometry assay, and in vivo experiments with nude mice. And messenger RNA (mRNA) high-throughput sequencing, RNA immunoprecipitation assay (RIP), luciferase assay, and a rescue experiment were used to identify the relationship between KIAA1429 and its specific targeted gene, c-Jun. We found that KIAA1429 was upregulated in gastric cancer tissues, and expressed lower in adjacent tissues. The upregulated KIAA1429 promoted proliferation and downregulated KIAA1429 was proved to inhibit proliferation of gastric cancer in vitro and in vivo. Then, we identified the potential KIAA1429 regulating gene as c-Jun by mRNAs high-throughput sequencing and RIP assay. By luciferase assay, we verified that KIAA1429 regulated the expression of c-Jun in an m6A-independent manner. Finally, the overexpression of c-Jun rescued the inhibition of proliferation caused by KIAA1429 knockdown in gastric cancer cells. KIAA1429 could act as an oncogene in gastric cancer by stabilizing c-Jun mRNA in an m6A-independent manner. This highlights the functional role for KIAA1429 as a potential prognostic biomarker and therapeutic target in gastric cancer.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  KIAA1429; c-Jun; gastric cancer; m6A independent manner

Year:  2020        PMID: 32052427     DOI: 10.1002/jcp.29645

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  22 in total

1.  Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.

Authors:  Chang Zhang; Qi Sun; Xu Zhang; Na Qin; Zhening Pu; Yayun Gu; Caiwang Yan; Meng Zhu; Juncheng Dai; Cheng Wang; Ni Li; Guangfu Jin; Hongxia Ma; Zhibin Hu; Erbao Zhang; Fengwei Tan; Hongbing Shen
Journal:  Cancer Commun (Lond)       Date:  2022-06-21

Review 2.  Progress and application of epitranscriptomic m6A modification in gastric cancer.

Authors:  Yitian Xu; Chen Huang
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

3.  Network Pharmacology Identifies the Mechanisms of Action of Tongxie Anchang Decoction in the Treatment of Irritable Bowel Syndrome with Diarrhea Predominant.

Authors:  Xiang Tan; Wenjing Pei; Chune Xie; Zhibin Wang; Tangyou Mao; Xingjie Zhao; Fushun Kou; Qiongqiong Lu; Zhongmei Sun; Xiaoxuan Xue; Junxiang Li
Journal:  Evid Based Complement Alternat Med       Date:  2020-11-17       Impact factor: 2.629

4.  Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m6A/p21 pathway.

Authors:  Lin Cheng; Xu Zhang; Yu-Zhou Huang; Yu-Lan Zhu; Ling-Yun Xu; Zhi Li; Xin-Yuan Dai; Liang Shi; Xu-Jie Zhou; Ji-Fu Wei; Qiang Ding
Journal:  Oncogenesis       Date:  2021-01-05       Impact factor: 7.485

5.  m6A RNA Methylation Regulators Act as Potential Prognostic Biomarkers in Lung Adenocarcinoma.

Authors:  Hongbo Wang; Xiangxuan Zhao; Zaiming Lu
Journal:  Front Genet       Date:  2021-02-10       Impact factor: 4.599

Review 6.  Role of m6A methyltransferase component VIRMA in multiple human cancers (Review).

Authors:  Wei Zhu; Jing-Zi Wang; Ji-Fu Wei; Chen Lu
Journal:  Cancer Cell Int       Date:  2021-03-17       Impact factor: 5.722

7.  Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases.

Authors:  Xiangsheng Zhang; Liye Zhong; Zhilin Zou; Guosheng Liang; Zhenye Tang; Kai Li; Shuzhen Tan; Yongmei Huang; Xiao Zhu
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

8.  Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR.

Authors:  Hailing Liu; Tian Lan; Hui Li; Lin Xu; Xing Chen; Haotian Liao; Xiangzheng Chen; Jinpeng Du; Yunshi Cai; Jinju Wang; Xuefeng Li; Jiwei Huang; Kefei Yuan; Yong Zeng
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

9.  N6-Methyladenosine RNA Demethylase FTO Promotes Gastric Cancer Metastasis by Down-Regulating the m6A Methylation of ITGB1.

Authors:  Duo Wang; Xiujuan Qu; Wenqing Lu; Yizhe Wang; Yue Jin; Kezuo Hou; Bowen Yang; Ce Li; Jianfei Qi; Jiawen Xiao; Xiaofang Che; Yunpeng Liu
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

10.  VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer.

Authors:  Daniela Barros-Silva; João Lobo; Catarina Guimarães-Teixeira; Isa Carneiro; Jorge Oliveira; Elena S Martens-Uzunova; Rui Henrique; Carmen Jerónimo
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.